A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Shen, Binghui, Ph.D. Bookmark and Share

Laboratory of Binghui Shen, Ph.D.

The Shen laboratory has carried out various major National Institutes of Health-funded projects. In addition, we collaborate with Dr. Yuejin Hua of Zhejiang University, China, in the study of radiation-induced DNA damage responses in Deinococcus radiodurans.
 
Research Environment
The laboratory is located in the Beckman Research Institute at City of Hope in Duarte, California. Duarte is in the northeast suburbs of Los Angeles, just outside Pasadena, nestled in the foothills of the San Gabriel mountains. We're close to all of the entertainment and scenic attractions Southern California has to offer, yet far enough removed from the big city buzz. Take a half hour drive to the beach, or an hour and a half to local skiing. The medical center and Beckman Research Institute are situated on a beautiful, 112-acre campus, and our lab is housed in the Kaplan-Black Research Building.
 
Approximately 25 NCI-supported core facilities are available for biomedical research in City of Hope as a Comprehensive Cancer Center research facility. These include: microarray, mass-spectroscopy/protein sequencing, DNA sequencing, oligonucleotide & peptide synthesis, phosphor- and fluoro-imaging, histology/histochemistry, frozen tumor bank, time-lapse videography, confocal and electron microscopies, cytogenetics, NMR, flow-cytometry, molecular modeling, transgenic mice, and animal care.
 
An active Postdoctoral Association (PDA) promotes interaction between the Institute and postdoctoral fellows and graduate students, to help to ensure that their transition is smooth and their time here is as fulfilling as possible
 

Binghui Shen, Ph.D. Research

DNA Replication, Repair, and Apoptosis Nucleases in Genome Stability and Cancer
DNA replication and repair are critical for maintaining genome stability. These processes are in part dependent on the activities of an emerging family of structure-specific nucleases. Flap EndoNuclease 1 (FEN1) is a metallo- and substrate structure specific- nuclease. It possesses three distinct biochemical activities, functioning as a flap endonuclease (FEN), a nick-specific exonuclease (EXO), and a gapdependent endonuclease (GEN). FEN1 plays a critical role in maintaining human genome stability via six different pathways. It serves as a major nuclease for RNA primer removal during Okazaki fragment maturation and for long patch base excision repair using its FEN activity. Its concerted action of EXO and GEN activities is critical in resolution of di- and tri- nucleotide repeat secondary structures and stalled DNA replication forks, as well as in apoptotic cell DNA fragmentation. It also plays a major role in maintenance of telomere stability.
 
The multiple functions of FEN1 are regulated via three major mechanisms: formation of complexes with different protein partners, cellular compartmentation, and post-translational modifications. More than 30 proteins have been identified to interact with FEN1, forming specific complexes in different pathways. Upon acetylation, FEN1 translocates into the nucleus in response to DNA damage and cell cycle phase changes. It is very much enhanced in the nucleolus for maintenance of stability of tandem repeats of ribosomal DNA. FEN1 is also in mitochondrion, playing an important role in mitochondrial DNA replication and repair. The nuclease is acetylated, phosphorylated or methylated in different molecular events and the interaction between methylation and phosphorylation determines its recruitment onto DNA replication forks via proliferating cell nuclear antigen. The first group of FEN1 somatic mutations has been identified in human cancer cells, which has clear segregation of biochemical activities. The future emphasis will be placed on the mutations and prevalent polymorphisms that may impair one of the three major regulatory mechanisms. See Project 1  - Functional Analysis of FEN-1 Nuclease in Genome Stability.
 
Recently, we found that another major nuclease, DNA2, is dominantly localized into mitochondria and cooperatively processes replication and repair DNA intermediates for ligation and completion of circular mtDNA replication and repair. These novel and exciting observations prompted us to: i) knock out the DNA2 gene in mice to determine if defective DNA2-mediated RNA primer removal causes mitochondrial genomic instabilities, consequently promoting cancers and other genetic diseases, and ii) link functional defects of the DNA2 mutations identified in human mitochondrion-based diseases to pathologic mechanisms. Information made available from these studies should establish a relationship among the functions of these novel mitochondrial genes, unique mitochondrial mutagenic phenotype(s), and pathological mechanisms. The proposed study may also establish a foundation for the development of new treatment regimens for patients with mitochondrion-based cancers and other disorders. See Project 2 - Role of Nucleases in RNA Primer Removal and Mutagenesis.
 
The other novel nuclease that we are interested in is called TatD, which possesses a nick and 3’ exonuclease activity and is involved in apoptosis DNA fragmentation. In collaboration with Dr. John Williams in the Department of Molecular Medicine, we are currently undertaking a detailed 3-D structural and functional analysis of TatD to determine its role in apoptosis and the biological consequences, in human cells, of defects in this nuclease.
 

Binghui Shen, Ph.D. Project 1

Functional analysis of FEN1 nuclease in genome stability
The project was funded by NCI to test a hypothesis that subtle deficiency or defects in the individual biochemical activities of FEN1 may lead to different phenotypes in yeast and different susceptibilities in the human population to environmental stresses and individual differences in the onset of genetic diseases.
 
Figure to the right: E160D FEN1 mice are highly susceptible to cancers as a result of their mutator phenotype and chronic inflammation. The panel shows the chronic inflammation and Tumorigenesis in the lung. Top, disease incidence at specific life stages (timeline in months) of wild-type (WT), Fen1ED/+ (ED/+) and Fen1ED/ED (ED/ED) mice. Below, histology (H&E) of normal lung, lung with chronic inflammation, adenoma and adenocarcinoma in ED/ED mice. From: Zheng et al., 2008 Nature Medicine.
 

Binghui Shen, Ph.D. Project 2

Role of nuclease in RNA primer removal and mutagenesis
The major goals of this project are to carry out experiments to test roles of several eukaryotic nuclease complexes in RNA primer removal during lagging strand DNA synthesis in nuclei and mitochondria, and to examine the mutagenic consequences of defects of the individual nuclease complexes.
 
Localization of hDNA2 and mitochondria-lspecific heat-shock protein 70 (mtHSP70) in HeLa cells. hDNA2 (red) and mtHSP70 (green) were stained with antibodies to hDNA2 and mtHSP70. The nucleus (blue) was stained with DAPI. Yellow spots (arrows) indicate co-localization of hDNA2 and mtHSP70 (merged views). The square box in the upper right panel is a magnification of the area framed in white.
 

Binghui Shen, Ph.D. Laboratory Members

Huifang Dai, B.S.
Sr. Research Associate
Ph 626-256-HOPE (4673), ext. 63818
Fax 626-301-8892
hdai@coh.org
 
Joonas Jamsen, Ph.D.
Postdoctoral Fellow
Ph. 626-256-HOPE (4673), ext. (W/A)
Fax 626-301-8892
jjamsen@coh.org
 
Weiqiang Lin, Ph.D.
Postdoctoral Fellow
Ph. 626-256-HOPE (4673), ext.64146
Fax 626-301-8892
wlin@coh.org
 
Guojun Lin, Ph.D.
Postdoctoral Fellow
Ph. 626-256-HOPE (4673), ext. 63818
Fax 626-301-8892
glu@coh.org
 
David Onyango, Ph.D.
Postdoctoral Fellow
Ph. 626-256-HOPE (4673), ext. 65284
Fax 626-301-8892
donyango@coh.org
 
Julie Kanjanapangka
Graduate Student
Ph 626-256-HOPE (4673), ext. 62935
Fax 626-301-8892
jkanjanapangka@coh.org
 
Zhenxing Wu, M.S.
Predoctoral Fellow
Ph. 626-256-HOPE (4673), ext. 63518
Fax 626-301-8892
zhwu@coh.org
 
Li Zheng, Ph.D.
Assistant Research Professor
Ph 626-256-HOPE (4673), ext. 64147
Fax 626-301-8892
lzheng@coh.org
 
Mian Zhou, Ph.D.
Staff Scientist
Ph 626-256-HOPE (4673), ext. 64147
Fax 626-301-8892
mzhou@coh.org
 

Shen, Binghui, Ph.D.

Laboratory of Binghui Shen, Ph.D.

The Shen laboratory has carried out various major National Institutes of Health-funded projects. In addition, we collaborate with Dr. Yuejin Hua of Zhejiang University, China, in the study of radiation-induced DNA damage responses in Deinococcus radiodurans.
 
Research Environment
The laboratory is located in the Beckman Research Institute at City of Hope in Duarte, California. Duarte is in the northeast suburbs of Los Angeles, just outside Pasadena, nestled in the foothills of the San Gabriel mountains. We're close to all of the entertainment and scenic attractions Southern California has to offer, yet far enough removed from the big city buzz. Take a half hour drive to the beach, or an hour and a half to local skiing. The medical center and Beckman Research Institute are situated on a beautiful, 112-acre campus, and our lab is housed in the Kaplan-Black Research Building.
 
Approximately 25 NCI-supported core facilities are available for biomedical research in City of Hope as a Comprehensive Cancer Center research facility. These include: microarray, mass-spectroscopy/protein sequencing, DNA sequencing, oligonucleotide & peptide synthesis, phosphor- and fluoro-imaging, histology/histochemistry, frozen tumor bank, time-lapse videography, confocal and electron microscopies, cytogenetics, NMR, flow-cytometry, molecular modeling, transgenic mice, and animal care.
 
An active Postdoctoral Association (PDA) promotes interaction between the Institute and postdoctoral fellows and graduate students, to help to ensure that their transition is smooth and their time here is as fulfilling as possible
 

Research

Binghui Shen, Ph.D. Research

DNA Replication, Repair, and Apoptosis Nucleases in Genome Stability and Cancer
DNA replication and repair are critical for maintaining genome stability. These processes are in part dependent on the activities of an emerging family of structure-specific nucleases. Flap EndoNuclease 1 (FEN1) is a metallo- and substrate structure specific- nuclease. It possesses three distinct biochemical activities, functioning as a flap endonuclease (FEN), a nick-specific exonuclease (EXO), and a gapdependent endonuclease (GEN). FEN1 plays a critical role in maintaining human genome stability via six different pathways. It serves as a major nuclease for RNA primer removal during Okazaki fragment maturation and for long patch base excision repair using its FEN activity. Its concerted action of EXO and GEN activities is critical in resolution of di- and tri- nucleotide repeat secondary structures and stalled DNA replication forks, as well as in apoptotic cell DNA fragmentation. It also plays a major role in maintenance of telomere stability.
 
The multiple functions of FEN1 are regulated via three major mechanisms: formation of complexes with different protein partners, cellular compartmentation, and post-translational modifications. More than 30 proteins have been identified to interact with FEN1, forming specific complexes in different pathways. Upon acetylation, FEN1 translocates into the nucleus in response to DNA damage and cell cycle phase changes. It is very much enhanced in the nucleolus for maintenance of stability of tandem repeats of ribosomal DNA. FEN1 is also in mitochondrion, playing an important role in mitochondrial DNA replication and repair. The nuclease is acetylated, phosphorylated or methylated in different molecular events and the interaction between methylation and phosphorylation determines its recruitment onto DNA replication forks via proliferating cell nuclear antigen. The first group of FEN1 somatic mutations has been identified in human cancer cells, which has clear segregation of biochemical activities. The future emphasis will be placed on the mutations and prevalent polymorphisms that may impair one of the three major regulatory mechanisms. See Project 1  - Functional Analysis of FEN-1 Nuclease in Genome Stability.
 
Recently, we found that another major nuclease, DNA2, is dominantly localized into mitochondria and cooperatively processes replication and repair DNA intermediates for ligation and completion of circular mtDNA replication and repair. These novel and exciting observations prompted us to: i) knock out the DNA2 gene in mice to determine if defective DNA2-mediated RNA primer removal causes mitochondrial genomic instabilities, consequently promoting cancers and other genetic diseases, and ii) link functional defects of the DNA2 mutations identified in human mitochondrion-based diseases to pathologic mechanisms. Information made available from these studies should establish a relationship among the functions of these novel mitochondrial genes, unique mitochondrial mutagenic phenotype(s), and pathological mechanisms. The proposed study may also establish a foundation for the development of new treatment regimens for patients with mitochondrion-based cancers and other disorders. See Project 2 - Role of Nucleases in RNA Primer Removal and Mutagenesis.
 
The other novel nuclease that we are interested in is called TatD, which possesses a nick and 3’ exonuclease activity and is involved in apoptosis DNA fragmentation. In collaboration with Dr. John Williams in the Department of Molecular Medicine, we are currently undertaking a detailed 3-D structural and functional analysis of TatD to determine its role in apoptosis and the biological consequences, in human cells, of defects in this nuclease.
 

Project 1

Binghui Shen, Ph.D. Project 1

Functional analysis of FEN1 nuclease in genome stability
The project was funded by NCI to test a hypothesis that subtle deficiency or defects in the individual biochemical activities of FEN1 may lead to different phenotypes in yeast and different susceptibilities in the human population to environmental stresses and individual differences in the onset of genetic diseases.
 
Figure to the right: E160D FEN1 mice are highly susceptible to cancers as a result of their mutator phenotype and chronic inflammation. The panel shows the chronic inflammation and Tumorigenesis in the lung. Top, disease incidence at specific life stages (timeline in months) of wild-type (WT), Fen1ED/+ (ED/+) and Fen1ED/ED (ED/ED) mice. Below, histology (H&E) of normal lung, lung with chronic inflammation, adenoma and adenocarcinoma in ED/ED mice. From: Zheng et al., 2008 Nature Medicine.
 

Project 2

Binghui Shen, Ph.D. Project 2

Role of nuclease in RNA primer removal and mutagenesis
The major goals of this project are to carry out experiments to test roles of several eukaryotic nuclease complexes in RNA primer removal during lagging strand DNA synthesis in nuclei and mitochondria, and to examine the mutagenic consequences of defects of the individual nuclease complexes.
 
Localization of hDNA2 and mitochondria-lspecific heat-shock protein 70 (mtHSP70) in HeLa cells. hDNA2 (red) and mtHSP70 (green) were stained with antibodies to hDNA2 and mtHSP70. The nucleus (blue) was stained with DAPI. Yellow spots (arrows) indicate co-localization of hDNA2 and mtHSP70 (merged views). The square box in the upper right panel is a magnification of the area framed in white.
 

Lab Members

Binghui Shen, Ph.D. Laboratory Members

Huifang Dai, B.S.
Sr. Research Associate
Ph 626-256-HOPE (4673), ext. 63818
Fax 626-301-8892
hdai@coh.org
 
Joonas Jamsen, Ph.D.
Postdoctoral Fellow
Ph. 626-256-HOPE (4673), ext. (W/A)
Fax 626-301-8892
jjamsen@coh.org
 
Weiqiang Lin, Ph.D.
Postdoctoral Fellow
Ph. 626-256-HOPE (4673), ext.64146
Fax 626-301-8892
wlin@coh.org
 
Guojun Lin, Ph.D.
Postdoctoral Fellow
Ph. 626-256-HOPE (4673), ext. 63818
Fax 626-301-8892
glu@coh.org
 
David Onyango, Ph.D.
Postdoctoral Fellow
Ph. 626-256-HOPE (4673), ext. 65284
Fax 626-301-8892
donyango@coh.org
 
Julie Kanjanapangka
Graduate Student
Ph 626-256-HOPE (4673), ext. 62935
Fax 626-301-8892
jkanjanapangka@coh.org
 
Zhenxing Wu, M.S.
Predoctoral Fellow
Ph. 626-256-HOPE (4673), ext. 63518
Fax 626-301-8892
zhwu@coh.org
 
Li Zheng, Ph.D.
Assistant Research Professor
Ph 626-256-HOPE (4673), ext. 64147
Fax 626-301-8892
lzheng@coh.org
 
Mian Zhou, Ph.D.
Staff Scientist
Ph 626-256-HOPE (4673), ext. 64147
Fax 626-301-8892
mzhou@coh.org
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • The physical side effects of cancer can damage anyone’s self-confidence, but especially that of women who, rightly or wrongly, are more likely to find their appearance (or their own perception of their appearance) directly connected to their ability to face the world with something resembling aplomb. Furt...
  • The promise of stem cell therapy has long been studied in laboratories. Now, as medicine enters an era in which this therapy will be increasingly available to patients, the nurses who help deliver it will be in the spotlight. City of Hope, which has launched its Alpha Clinic for Cell Therapy and Innovation (ACT...
  • Just because you can treat a condition, such as high cholesterol, at the end of life — well, that doesn’t mean you should. That’s the basic lesson of a study to be published March 30 in JAMA Internal Medicine. The ramifications go far beyond that. The research, in which City of Hope’s Betty Fe...
  • The understanding of the relationship between genetics and cancer risk continues to grow, with more genetic testing than ever before available to patients. However, the adage that a little knowledge is a dangerous thing is applicable: Without context for what a test result means, and without meaningful guidance...
  • Standard prostate biopsies haven’t changed significantly in the past 30 years – nor have the problems inherent with them. Regular biopsies have an expected error rate: Tumors may potentially be undersampled and, 30 percent of the time, men who undergo a radical prostatectomy are found to have more aggress...
  • In the field of cancer, patients have had surgery, chemotherapy and radiation therapy as options. Now, as City of Hope officially opens the Alpha Clinic for Cellular Therapy and Innovation, patients battling cancer and other life-threatening diseases have another option: stem-cell-based therapy. The Alpha Clini...
  • How does the environment affect our health? Specifically, how does it affect our risk of cancer? City of Hope physicians and researchers recently answered those questions in an Ask the Experts event in Corona, California, explaining the underlying facts about how the environment can affect our health. Moderator...
  • Nurses and other medical professionals have come to understand that it’s not enough just to fight disease. They also must provide pain relief, symptom control, and an unrelenting commitment to improve patients’ quality of life — especially at the end of life. Not too long ago, this was a relatively ...
  • “Tonight, I’m launching a new precision medicine initiative to bring us closer to curing diseases like cancer.” These were the words of President Barack Obama on Jan. 20, 2015, during his State of the Union address. So what is precision medicine, and how close are we to making it a reality for...
  • March is Colon Cancer Awareness Month. How sad, yet how serendipitous, that the co-creator of “The Simpsons” Sam Simon passed away in March after a four-year battle against colon cancer. What message can we all learn from his illness that can help us prevent and overcome colon cancer in our own lives? Colon can...
  • Misagh Karimi, M.D., assistant clinical professor, is a medical oncologist at one of City of Hope’s newest community practice locations, located in Corona in Riverside County. A recent community health report from Corona’s public health department stated that obesity rates for teens and adults in Riverside Coun...
  • In 1975, the median survival for patients with ovarian cancer was about 12 months. Today, the median survival is more than 5 years. Although researchers and clinicians are far from satisfied, the progress in ovarian cancer treatment is encouraging, said Robert Morgan, M.D., F.A.C.P., professor of medical oncolo...
  • Colorectal cancer may be one of the most common cancers in both men and women, but it’s also one of the most curable cancers. Today, because of effective screening tests and more advanced treatment options, there are more than 1 million survivors of colorectal cancer in the United States. Here, colorectal...
  • Breast cancer treatment can damage a woman’s ability to become pregnant, making the impact on fertility one of the key factors that many consider when choosing a therapy regimen. Now a study has found that breast cancer patients treated with a hormone-blocking drug in addition to chemotherapy were less li...
  • My colleagues in the clinic know I’ve got a soft spot. Last week, a patient of mine offered me a fantastic compliment. “You’re looking younger these days, Dr. Pal!” she said, offering me a big hug as she proceeded out of the clinic room. Lovely, I thought. The early morning workouts are paying off. She continue...